Bile Duct Neoplasms Clinical Trial
Official title:
SAFETY AND EFFICACY OF INTRA DUCTAL RADIO FREQUENCY ABLATION IN UNRESECTABLE MALIGNANT BILIARY OBSTRUCTION: PROSPECTIVE OBSERVATIONAL STUDY
Endoscopic retrograde cholangio pancreatography procedure will performed as per local standard procedure.After common bile duct cannulation,cholangiography will be performed (to confirm the stricture) followed by biliary sphincterotomy. All biliary strictures(Bismuth Type I/II/III/IV) will be enrolled for the study. Patient opting for Uncovered self expandable metallic stent / Plastic stent will undergo biliary stent placement and considered under control arm Patient opting for radio frequency ablation + Uncovered SEMS/Plastic stent will undergo radio frequency ablation and biliary stent placement and considered under Study arm The RFA probe will be inserted into the bile duct alongwith the guidewire. Keeping the electrode overlapping the stricture, RFA will be performed using a power of 10W for 120 seconds. The electrode will be kept at the ablation site for an additional 1 minute to allow the RFA probe to cool before removal to prevent thermal injury of normal tissue and/or endoscope accessory channel. If the stricture is more than 3 cm, step-by-step RFA will be performed from the superior to inferior aspect. After RFA application, an uncovered SEMS/Plastic stent will be placed.
Placement of self expandable metallic stent is the standard of care in the palliative management of patients with malignant biliary strictures . Relieves biliary obstruction and jaundice. Self expandable metallic stent provide efficient drainage and have superior patency rates compared with the plastic stents Endoscopic radio frequency ablation combined with stent placement can significantly prolong survival and the stent patency period without increasing the incidence of adverse events in patients with extra hepatic cholangiocarcinoma patient. Compared to plastic/ metal stent placement alone the addition of radio frequency ablation to stent placement would have better outcomes. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05600803 -
Screening Single-operator Cholangioscopy for Neoplastic Bile Duct Lesions
|
||
| Recruiting |
NCT05286814 -
M9241 in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer or Intrahepatic Cholangiocarcinoma
|
Phase 2 | |
| Recruiting |
NCT06115655 -
A Single-center, Prospective Cohort Study on the Differentiation of Benign and Malignant Bile Duct Stenosis Based on Bile and Peripheral Blood cfDNA Methylation Profiles
|
||
| Enrolling by invitation |
NCT03951324 -
Volumetric Laser Endomicroscopy's (VLE) Diagnostic Accuracy Validation Study: Impact on Clinical Management Study
|
||
| Active, not recruiting |
NCT05374122 -
AI Guidance for Biopsy in Suspected Cholangiocarcinoma
|
N/A | |
| Terminated |
NCT04276090 -
Codman Catheter/Synchromed Pump Hepatic Artery Chemotherapy for Unresectable Colorectal Metastases/Intrahepatic Cholangiocarcinoma
|
N/A | |
| Completed |
NCT01232101 -
Covered or Uncovered Bile Duct Stents
|
N/A | |
| Active, not recruiting |
NCT00582647 -
Collection of Tissue & Blood From Patients w/ Benign & Malignant Tumors of the Soft Tissue & Gastrointestinal Tract
|
||
| Recruiting |
NCT00915863 -
Evaluation of Isolated Roux-en-Y Reconstruction After Pancreaticoduodenectomy
|
N/A | |
| Recruiting |
NCT05172310 -
PET Imaging of Solid Tumors by a Novel Tracer, 68Ga-FAPI
|
Phase 1 | |
| Completed |
NCT01845337 -
Study to Compare Cardiovascular Side Effects of Teysuno Versus Capecitabine
|
Phase 2 | |
| Completed |
NCT04847167 -
Mechanistic Loop Resolution Strategy for Short-type Single Balloon Enteroscopy
|
N/A | |
| Completed |
NCT00634751 -
CO07204-Phase I/II of Oxaliplatin, Capecitabine & Sorafenib for Advanced Pancreatic & Biliary Carcinoma
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT03838913 -
Whole-Exome Sequencing (WES) of Intraductal Neoplasms of the Bile Duct (IPNB)
|